Literature DB >> 22156532

Production of infectious chimeric hepatitis C virus genotype 2b harboring minimal regions of JFH-1.

Asako Murayama1, Takanobu Kato, Daisuke Akazawa, Nao Sugiyama, Tomoko Date, Takahiro Masaki, Shingo Nakamoto, Yasuhito Tanaka, Masashi Mizokami, Osamu Yokosuka, Akio Nomoto, Takaji Wakita.   

Abstract

To establish a cell culture system for chimeric hepatitis C virus (HCV) genotype 2b, we prepared a chimeric construct harboring the 5' untranslated region (UTR) to the E2 region of the MA strain (genotype 2b) and the region of p7 to the 3' UTR of the JFH-1 strain (genotype 2a). This chimeric RNA (MA/JFH-1.1) replicated and produced infectious virus in Huh7.5.1 cells. Replacement of the 5' UTR of this chimera with that from JFH-1 (MA/JFH-1.2) enhanced virus production, but infectivity remained low. In a long-term follow-up study, we identified a cell culture-adaptive mutation in the core region (R167G) and found that it enhanced virus assembly. We previously reported that the NS3 helicase (N3H) and the region of NS5B to 3' X (N5BX) of JFH-1 enabled replication of the J6CF strain (genotype 2a), which could not replicate in cells. To reduce JFH-1 content in MA/JFH-1.2, we produced a chimeric viral genome for MA harboring the N3H and N5BX regions of JFH-1, combined with a JFH-1 5' UTR replacement and the R167G mutation (MA/N3H+N5BX-JFH1/R167G). This chimeric RNA replicated efficiently, but virus production was low. After the introduction of four additional cell culture-adaptive mutations, MA/N3H+N5BX-JFH1/5am produced infectious virus efficiently. Using this chimeric virus harboring minimal regions of JFH-1, we analyzed interferon sensitivity and found that this chimeric virus was more sensitive to interferon than JFH-1 and another chimeric virus containing more regions from JFH-1 (MA/JFH-1.2/R167G). In conclusion, we established an HCV genotype 2b cell culture system using a chimeric genome harboring minimal regions of JFH-1. This cell culture system may be useful for characterizing genotype 2b viruses and developing antiviral strategies.

Entities:  

Mesh:

Year:  2011        PMID: 22156532      PMCID: PMC3302416          DOI: 10.1128/JVI.05386-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Down-regulation of translation driven by hepatitis C virus internal ribosomal entry site by the 3' untranslated region of RNA.

Authors:  K Murakami; M Abe; T Kageyama; N Kamoshita; A Nomoto
Journal:  Arch Virol       Date:  2001       Impact factor: 2.574

2.  Sequence motifs required for lipid droplet association and protein stability are unique to the hepatitis C virus core protein.

Authors:  R Graham Hope; John McLauchlan
Journal:  J Gen Virol       Date:  2000-08       Impact factor: 3.891

3.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.

Authors:  Takaji Wakita; Thomas Pietschmann; Takanobu Kato; Tomoko Date; Michiko Miyamoto; Zijiang Zhao; Krishna Murthy; Anja Habermann; Hans-Georg Kräusslich; Masashi Mizokami; Ralf Bartenschlager; T Jake Liang
Journal:  Nat Med       Date:  2005-06-12       Impact factor: 53.440

4.  Robust hepatitis C virus infection in vitro.

Authors:  Jin Zhong; Pablo Gastaminza; Guofeng Cheng; Sharookh Kapadia; Takanobu Kato; Dennis R Burton; Stefan F Wieland; Susan L Uprichard; Takaji Wakita; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

5.  Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.

Authors:  K Kiyosawa; T Sodeyama; E Tanaka; Y Gibo; K Yoshizawa; Y Nakano; S Furuta; Y Akahane; K Nishioka; R H Purcell
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

6.  Comparison between subgenomic replicons of hepatitis C virus genotypes 2a (JFH-1) and 1b (Con1 NK5.1).

Authors:  Michiko Miyamoto; Takanobu Kato; Tomoko Date; Masashi Mizokami; Takaji Wakita
Journal:  Intervirology       Date:  2006       Impact factor: 1.763

7.  Real-time detection system for quantification of hepatitis C virus genome.

Authors:  T Takeuchi; A Katsume; T Tanaka; A Abe; K Inoue; K Tsukiyama-Kohara; R Kawaguchi; S Tanaka; M Kohara
Journal:  Gastroenterology       Date:  1999-03       Impact factor: 22.682

8.  Complete replication of hepatitis C virus in cell culture.

Authors:  Brett D Lindenbach; Matthew J Evans; Andrew J Syder; Benno Wölk; Timothy L Tellinghuisen; Christopher C Liu; Toshiaki Maruyama; Richard O Hynes; Dennis R Burton; Jane A McKeating; Charles M Rice
Journal:  Science       Date:  2005-06-09       Impact factor: 47.728

9.  Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

Authors:  V Lohmann; F Körner; J Koch; U Herian; L Theilmann; R Bartenschlager
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

10.  Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection.

Authors:  T Murakami; N Enomoto; M Kurosaki; N Izumi; F Marumo; C Sato
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

View more
  8 in total

1.  Construction of a chimeric hepatitis C virus replicon based on a strain isolated from a chronic hepatitis C patient.

Authors:  Huang Cao; Wandi Zhu; Qingxia Han; Rongjuan Pei; Xinwen Chen
Journal:  Virol Sin       Date:  2014-01-20       Impact factor: 4.327

2.  Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system.

Authors:  Yi-Ping Li; Santseharay Ramirez; Sanne B Jensen; Robert H Purcell; Judith M Gottwein; Jens Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-14       Impact factor: 11.205

3.  Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.

Authors:  Judith M Gottwein; Sanne B Jensen; Stéphanie B N Serre; Lubna Ghanem; Troels K H Scheel; Tanja B Jensen; Henrik Krarup; Nathalie Uzcategui; Lotte S Mikkelsen; Jens Bukh
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

4.  Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies.

Authors:  Jannie Pedersen; Thomas H R Carlsen; Jannick Prentoe; Santseharay Ramirez; Tanja B Jensen; Xavier Forns; Harvey Alter; Steven K H Foung; Mansun Law; Judith Gottwein; Nina Weis; Jens Bukh
Journal:  Hepatology       Date:  2013-08-07       Impact factor: 17.425

5.  A novel strategy to develop a robust infectious hepatitis C virus cell culture system directly from a clinical isolate.

Authors:  Jie Lu; Yu Xiang; Wanyin Tao; Qingchao Li; Na Wang; Yongfeng Gao; Xiaogang Xiang; Qing Xie; Jin Zhong
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

6.  Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors.

Authors:  Long V Pham; Santseharay Ramirez; Thomas H R Carlsen; Yi-Ping Li; Judith M Gottwein; Jens Bukh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

7.  Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.

Authors:  Judith M Gottwein; Sanne B Jensen; Yi-Ping Li; Lubna Ghanem; Troels K H Scheel; Stéphanie B N Serre; Lotte Mikkelsen; Jens Bukh
Journal:  Antimicrob Agents Chemother       Date:  2012-12-28       Impact factor: 5.191

8.  A subclone of HuH-7 with enhanced intracellular hepatitis C virus production and evasion of virus related-cell cycle arrest.

Authors:  Asako Murayama; Nao Sugiyama; Seiko Yoshimura; Mitsuko Ishihara-Sugano; Takahiro Masaki; Sulyi Kim; Takaji Wakita; Shunji Mishiro; Takanobu Kato
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.